Teva Submits NDA for Ecopipam After Phase 3 Tourette Results
TEVA•Teva submitted its NDA to FDA for ecopipam, a first-in-class dopamine D1 antagonist for pediatric Tourette syndrome, based on Phase 3 data showing a significant delay in relapse (p=0.008). The therapy has Orphan Drug and Fast Track designations and could be the first new pediatric Tourette treatment in a decade.
1. NDA Submission
On June 18, 2026 Teva filed a New Drug Application with the FDA for ecopipam to treat pediatric Tourette syndrome. This submission marks a key milestone in Teva’s Pivot to Growth strategy by advancing a novel therapy acquired to expand its innovative biopharmaceutical pipeline.
2. Phase 3 Trial Results
The NDA is supported by Phase 3 data showing ecopipam significantly delayed time to relapse versus placebo in responding pediatric patients, achieving statistical significance on the primary efficacy endpoint (p=0.008). The study reported commonly observed adverse events such as somnolence, anxiety, headache, insomnia and fatigue.
3. Regulatory Designations and Market Potential
Ecopipam holds FDA Orphan Drug and Fast Track designations for pediatric Tourette syndrome, potentially expediting review and exclusivity. If approved, it would become the first new treatment for this indication in over a decade, opening a market for children who currently have limited therapeutic options.
